Holen Sie sich die Stockscreener-App
8.55
0.12%
-0.010
Handel nachbörslich:
8.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.56
Offen:
$8.49
24-Stunden-Volumen:
1.13M
Relative Volume:
0.62
Marktkapitalisierung:
$1.11B
Einnahmen:
$727.33M
Nettoeinkommen (Verlust:
$-108.03M
KGV:
-10.13
EPS:
-0.844
Netto-Cashflow:
$-21.78M
1W Leistung:
-6.04%
1M Leistung:
-25.33%
6M Leistung:
+2.52%
1J Leistung:
-21.42%
1-Tages-Spanne:
$8.43
$8.65
1-Wochen-Bereich:
$8.43
$9.38
52-Wochen-Spanne:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.55 | 1.11B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
495.72 | 185.77B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.06 | 138.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
600.52 | 47.68B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.42 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
297.54 | 29.39B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics at Leerink Conference: Strategic Growth Focus - Investing.com
Investment Recap: Is NeoGenomics Inc gaining market share2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Insider Sell: Can NeoGenomics Inc deliver alphaMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
GW&K Investment Management LLC Cuts Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
Royce & Associates LP Sells 860,000 Shares of NeoGenomics, Inc. $NEO - MarketBeat
Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
NeoGenomics (NEO) accounting chief granted new options and RSUs - Stock Titan
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan
NeoGenomics (NEO) COO receives new stock option and RSU grants - Stock Titan
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan
NeoGenomics at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
NeoGenomics at TD Cowen Conference: Strategic Growth Insights - Investing.com South Africa
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch - simplywall.st
NeoGenomics Stock Price Drops Below 200-Day Average - National Today
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan
Oversold Conditions For NeoGenomics (NEO) - Nasdaq
NEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NEO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Earnings are out: How did SWFL companies perform? - Naples Daily News
Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test - Bloomberg Law News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Yahoo Finance
(NEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tu - PharmiWeb.com
NeoGenomics Launches RaDaR ST Molecular Residual Disease Test - marketscreener.com
NeoGenomics, Inc. Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - marketscreener.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - The Joplin Globe
NeoGenomics, Inc. Trade Ideas — FWB:NG9 - TradingView
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction - MSN
NeoGenomics (NEO) COO logs RSU vesting and tax share withholding - Stock Titan
Equity moves for NeoGenomics (NASDAQ: NEO) CFO Jeffrey Sherman - Stock Titan
NeoGenomics (NEO) EVP nets new shares from RSU vesting and tax withholding - Stock Titan
NeoGenomics (NEO) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
NeoGenomics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call - Finviz
NeoGenomics, Inc. (NEO) Stock Analysis: A 47% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call - Yahoo Finance
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - Yahoo Finance
NeoGenomics, Inc. $NEO Shares Bought by White Pine Capital LLC - MarketBeat
NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc - MarketBeat
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Finviz
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Why is NeoGenomics Inc. stock going upM&A Rumor & Free High Accuracy Swing Entry Alerts - mfd.ru
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock - Defense World
NeoGenomics Q4 Earnings Call Highlights - Defense World
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):